PMID- 30783417
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 17
IP  - 3
DP  - 2019 Mar
TI  - Allicin suppresses the migration and invasion in cervical cancer cells mainly by 
      inhibiting NRF2.
PG  - 1523-1528
LID - 10.3892/etm.2018.7104 [doi]
AB  - Emerging evidence has demonstrated the antitumor activity of allicin in various 
      tumors. However, little study has been carried out on the functional role of 
      allicin in cervical cancer. Our data showed that allicin suppressed cervical 
      cancer cell viability in a time- and dose-dependent manner. Allicin treatment 
      could reverse H(2)O(2)-induced reactive oxygen species accumulation. Meanwhile, 
      levels of glutathione and superoxide dismutase were increased, but 
      malondialdehyde was decreased after allicin incubation for 48 h. Furthermore, 
      TUNEL staining showed that H(2)O(2) treatment induced cell apoptosis, but allicin 
      treatment could decrease cell apoptosis. Western blot assay showed that allicin 
      could suppress the expression of nuclear factor erythroid 2-related factor 2 
      (NRF2) and heme oxygenase 1. We also showed that NRF2 prompted SiHa cell 
      proliferation and reduced SiHa cell apoptosis. More importantly, 
      allicin-inactivated phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) 
      signaling could be partially reversed by overexpressing of NRF2. We also 
      evaluated cell apoptosis in SiHa cells transfected with plasmid NRF2. Our data 
      showed that allicin-induced cell apoptosis (43.5+/-3.8%) could largely be abolished 
      by upregulation of NRF2 (12.3+/-2.08%). In summary, our data showed allicin was 
      effective in suppressing the malignant phenotype of cervical cancer cells mainly 
      by inhibiting the expression of NRF2, showing the potential clinical benefits of 
      allicin in cervical cancer patients.
FAU - Zhang, Qiumei
AU  - Zhang Q
AD  - Outpatient Department of Obstetrics and Gynecology, Linyi People's Hospital, 
      Linyi, Shandong 276000, P.R. China.
FAU - Yang, Dongmei
AU  - Yang D
AD  - Outpatient Department of Obstetrics and Gynecology, Linyi People's Hospital, 
      Linyi, Shandong 276000, P.R. China.
AD  - Second Department of Gynecology, Linyi People's Hospital, Linyi, Shandong 276000, 
      P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20181217
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC6364242
OTO - NOTNLM
OT  - allicin
OT  - cervical cancer
OT  - nuclear factor erythroid 2-related factor 2
OT  - oxidative stress
EDAT- 2019/02/21 06:00
MHDA- 2019/02/21 06:01
PMCR- 2018/12/17
CRDT- 2019/02/21 06:00
PHST- 2017/08/01 00:00 [received]
PHST- 2017/10/18 00:00 [accepted]
PHST- 2019/02/21 06:00 [entrez]
PHST- 2019/02/21 06:00 [pubmed]
PHST- 2019/02/21 06:01 [medline]
PHST- 2018/12/17 00:00 [pmc-release]
AID - ETM-0-0-7104 [pii]
AID - 10.3892/etm.2018.7104 [doi]
PST - ppublish
SO  - Exp Ther Med. 2019 Mar;17(3):1523-1528. doi: 10.3892/etm.2018.7104. Epub 2018 Dec 
      17.